Method of reducing bacterial activity in the oral cavity of a patient
US-2024041702-A1 · Feb 8, 2024 · US
US10105390B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10105390-B2 |
| Application number | US-201515327817-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 21, 2015 |
| Priority date | Jul 21, 2014 |
| Publication date | Oct 23, 2018 |
| Grant date | Oct 23, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Process for obtaining fluoride-doped citrate-coated amorphous calcium phosphate nanoparticles. This material has applications in biomedicine due to its biodegradability and bioactivity; it also promotes cell adhesion and osteogeneration. In dentistry, it may be used in toothpastes, mouthwashes, chewing gums, gels and fluoride varnishes as a remineralising agent of dentine and enamel. It is based on two solutions formed by calcium chloride and sodium citrate on the one hand, and by sodium monohydrogenophosphate and sodium carbonate with a fluoride compound on the other, which are mixed at room temperature. The process is eco-efficient and eco-friendly, as it does not leave any acid residue; it consists of a single stage and it is the first time that an amorphous calcium phosphate coated with citrate and doped with fluoride, which enhances its remineralising action, is obtained.
Opening claim text (preview).
The invention claimed is: 1. A process for obtaining fluoride-doped citrate-coated amorphous calcium phosphate nanoparticles comprising: preparing a first solution comprising CaCl 2 at a concentration comprised between 0.08 M and 0.12 M and Na 3 C 6 H 5 O 7 at a concentration comprised between 0.35 M and 0.50 M; preparing a second solution comprising Na 2 HPO 4 at a concentration comprised between 0.10 M and 0.15 M, Na 2 CO 3 at a concentration of 0.2 M and a fluoride compound; mixing under stirring the two solutions prepared in the previous stages in the proportion 1:1 v/v at a pH comprised between 8.3 and 8.7 at ambient temperature for a time period of less than 2 minutes; performing three successive sedimentation cycles of the mixture of the two solutions formed in the previous step by centrifugation, removal of the obtained supernatant and washing of the obtained precipitate using ultrapure water; and freeze-drying the wet precipitate obtained in the previous step. 2. The process according to claim 1 , characterised in that the concentrations used for the first solution are 0.1 M for CaCl 2 and 0.4 M for Na 3 C 6 H 5 O 7 . 3. The process according to claim 1 , characterised in that the concentrations used for the second solution are 0.12 M for Na 2 HPO 4 and 0.2 M for Na 2 CO 3 . 4. The process according to claim 1 , characterised in that the fluoride compound is selected from among CaF 2 , NaF and KF and is added to a concentration comprised between 0.01 M and 0.1 M. 5. The process according to claim 4 , characterised in that the fluoride compound is CaF 2 which is added to a concentration of 0.05 M. 6. Citrate-coated and fluoride-doped amorphous calcium phosphate nanoparticles obtained by a process comprising: preparing a first solution comprising CaCl 2 at a concentration comprised between 0.08 M and 0.12 M and Na 3 C 6 H 5 O 7 at a concentration comprised between 0.35 M and 0.50 M; preparing a second solution comprising Na 2 HPO 4 at a concentration comprised between 0.10 M and 0.15 M, Na 2 CO 3 at a concentration of 0.2 M, and a fluoride compound; mixing under stirring the two solutions prepared in the previous stages in the proportion 1:1 v/v at a pH comprised between 8.3 and 8.7 at ambient temperature for a time period of less than 2 minutes; performing three successive sedimentation cycles of the mixture of the two solutions formed in the previous step by centrifugation, removal of the obtained supernatant and washing of the obtained precipitate using ultrapure water; and freeze-drying the wet precipitate obtained in the previous step, characterised in that they have a spherical shape and a size comprised between 30 nm and 80 nm and sodium, calcium, and phosphate, citrate, carbonate, fluoride and water content comprised: between 3.1% and 3.5% by weight of sodium between 27.0% and 27.4% by weight of calcium between 37.0% and 37.8% by weight of phosphate (P) between 3.5% and 5.0% by weight of citrate between 5.4% and 7.0% by weight of carbonate between 6% and 10% by weight of water, and between 2% and 5% by weight of fluoride. 7. A vehicle for biomolecules, drugs, or both comprising the citrate-coated and fluoride-doped amorphous calcium phosphate nanoparticles as defined in claim 6 . 8. A biomaterial comprising the fluoride-doped citrate-coated amorphous calcium phosphate nanoparticles as defined in claim 6 . 9. The biomaterial according to claim 8 , wherein the biomaterial is orthopaedic or dental. 10. A composition comprising the citrate-coated and fluoride-doped amorphous calcium phosphate nanoparticles as defined in claim 6 . 11. The composition according to claim 10 , wherein the composition is toothpaste, chewing gum, mouthwash, fluoride varnish, or gel.
Phosphate cements (apatite A61K6/838) · CPC title
Particle size · CPC title
Filling; Sealing · CPC title
Protective coatings for natural or artificial teeth, e.g. sealings, dye coatings or varnish · CPC title
Processes · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.